Selidji Todagbe AGNANDJI

I am happy and excited to be the leader of a joint professorship of Tropical Microbiology of the Medical University of Münster and the CERMEL. I value interdisciplinary and global scientific collaborations involving senior, midterms and junior scientists and students. I value fair partnership and societal engagement in science.

Developing a community-based literacy course in biomedical research to engage societies in biomedical sciences

Designing clinical trials that match multidisciplinary stakeholders´ interests

Medical editor for Frontiers in immunology

Advocacy to make clinical trials as public norm for evidence based decisions in Africa

• Georg Forster Research Award, Alexander Von Humboldt Stiftung, Germany, 2022
• EDCTP Senior Fellow, 01/2020, European Developing Countries Clinical Trials Partnership,
• Ambassador of the University of Tübingen for West and Central Africa (03/2019 - Present), Eberhard Karls University, Tuebingen, Germany.
• Prize of Excellence of the Gabonese Council of Science, 06/2015, Centre National de la Recherche Scientifique et Technologique du Gabon

• Certification of the Necator americanus L3 larvae production by the National Pharmaceutical Agency in Gabon, in process

• ADAPT VAC, Development of Broadly Protective Filovirus Vaccines. CEPI funded project starting in September 2025
• WORMVACS2.0 (Project ID 101080784). Duration: 2023-2026. This is EU funded project entitled Innovations for vaccines against helminth infections. A multicenter project coordinated by the LUMC under the lead of Prof Ron Hokke. I am the principal investigator for CERMEL. Amount: 700000 Euro
• EChiLiBRiST
  This is an EU-funded project. The grant signature is ongoing. The partnership includes eight institutions which will work on the "Development and validation of a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival"
• VARSAF ,Strengthening vaccine research at CERMEL focusing on biomedical and social sciences, five year senior fellowship project, reference TMA2017SF-1946, funded by EDCTP
• 
  

• Agnandji ST, Loembe MM, Mbouna AV, et al. Making clinical trials a public norm for health decisions in sub-Saharan Africa. Frontiers in Tropical Diseases 2024; 4.
• Otogo N’nang E, Essone PN, Ella Ndong J, et al. LC-MS based analysis reveal antimicrobial compounds from Gabonese pharmacopoeia: chemical characterisation and cytotoxicity evaluation. Frontiers in Natural Products 2025; 3: 1478361.
• Alabi A, Musangomunei FP, Lotola-Mougeni F, et al. Performance evaluation of a combination Plasmodium dual-antigen CRP rapid diagnostic test in Lambaréné, Gabon. Infection 2025; 53(1): 285-95.
• Mayr W, Ndong PE, Alabi A, Kabwende LA, Weiss G, Agnandji ST. Iron homeostasis and cytokine responses in Gabonese children with febrile illness. Commun Med (Lond) 2025; 5(1): 305.
• Agnandji ST, Essone PN, Medaglini D, Massinga Loembe M. Readiness in preventing filovirus epidemics by use of the marketed vaccines against Zaire Ebola virus disease as prototypes. Lancet Infect Dis 2024; 24(7): 671-3.
• Alabi A, Kokou K, Mahmoudou S, et al. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon. J Infect 2024; 89(4): 106237.
• Agnandji ST, Recker M, Mordmüller B, et al. Prostration and the prognosis of death in African children with severe malaria. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023; 134: 240-7.
• Agnandji ST, Loembe MM. Ebola vaccines for mass immunisation in affected regions. Lancet Infect Dis 2022; 22(1): 8-10.
• Essone PN, Adegbite BR, Mbadinga MJM, et al. Creatine kinase-(MB) and hepcidin as candidate biomarkers for early diagnosis of pulmonary tuberculosis: a proof-of-concept study in Lambaréné, Gabon. Infection 2022; 50(4): 897-905.
• Alabi A, Hussain M, Hoogerwerf MA, et al. Establishing a controlled hookworm human infection (CHHI) model for Africa: A report from the stakeholders meeting held in Lambaréné, Gabon, November 10-11, 2019. Arch Public Health 2021; 79(1): 120.